00:20 , Aug 2, 2019 |  BC Innovations  |  Distillery Techniques

Genetic biomarkers for anorexia nervosa

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: SNPs; gene profiling SNPs in eight genomic regions could predict risk of anorexia nervosa. The loci were identified in a meta-analysis of 33 genome-wide association studies (GWAS) covering 16,992 anorexic patients...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
13:55 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

UBR7 and CDH4 as targets for triple-negative breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest UBR7 or its downstream mediator CDH4 could help treat triple-negative breast cancer (TNBC). In tumor samples from patients with TNBC or...
02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest an oncolytic herpes simplex virus (HSV) expressing CDH1 could help treat glioblastoma multiforme (GBM). An oncolytic HSV was engineered to express human CDH1 to enhance cell-to-cell transmission and reduce...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
20:33 , Oct 31, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models E-cadherin (CDH1)-deficient mice with activated PI3KCA could be used to screen therapies for invasive lobular breast carcinoma. Mice engineered to express mutant, inactive CHD1 and constitutively active PI3KCA recapitulated multiple features of...
18:27 , Oct 19, 2018 |  BC Week In Review  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
21:29 , Oct 17, 2018 |  BC Extra  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...